Archive for July 2018
Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
The Andarix drug addresses the growing Lung Cancer problem in Asia SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto,…
Read MoreAndarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29…
Read MoreAndarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…
Read MoreAndarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA
Expanding Opportunities in Asia SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018…
Read More